Filing Details

Accession Number:
0001209191-19-061213
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-18 20:05:17
Reporting Period:
2019-12-16
Accepted Time:
2019-12-18 20:05:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
897448 Amarin Corp Plc AMRN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1331852 S Joseph Zakrzewski C/o Amarin Pharma, Inc.
440 Us Highway 22
Bridgewater NJ 08807
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2019-12-16 100,000 $9.00 184,547 No 4 M Direct
Ordinary Shares Disposition 2019-12-16 100,000 $25.83 84,547 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Acquisiton 2019-12-16 100,000 $0.00 100,000 $9.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
138,542 2021-10-20 No 4 M Direct
Footnotes
  1. The option exercises and sale transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
  2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.80 to $25.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. Please see the section title "Remarks" below for additional information.
  5. The stock option granted to the Reporting Person is fully vested as of the date hereof.